Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2002-08-05
2009-06-02
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S196110, C424S208100
Reexamination Certificate
active
07541036
ABSTRACT:
New isolated polypeptides of the protein p17 of HIV are described, represented by the formula: NH2-X1-Gly-X2-X3-Leu-Asp-X4-Trp-Glu-X5-Ile-X6-Leu-Arg-COOH (SEQ ID NO:1) in which X1is an amino acid residue selected from Ser and Arg; X2is an amino acid residue selected from Gly, Glu and Ser; X3is an amino acid residue selected from Glu, Lys, Asp and Arg; X4is an amino acid residue selected from Arg, Ala, Lys, Thr, Ser, Glu, Asp and Gln; X5is an amino acid residue selected from Lys, Arg and Ser; and X6is an amino acid residue selected from Arg and Gln. These polypeptides, when administered to a subject, are able to evoke anti-p17 neutralizing antibodies and are therefore useful as vaccine or inoculum. Monoclonal and polycolonal anti-p17 antibodies which are able to neutralize the biological activity of this viral protein and to recognize its neutralization epitope in a specific manner are also described.
REFERENCES:
patent: 6268472 (2001-07-01), Zimmerman et al.
patent: 0 426 314 (1991-05-01), None
patent: 0 620 009 (1994-10-01), None
patent: 0 620 009 (1994-10-01), None
Ghose, A. C., and F. Karush, 1988, “Induction of polyclonal and monoclonal antibody responses to cholera toxin by the synthetic peptide approach”, Mol. Immunol. 25(3):223-230 (abstract provided).
Gorse, G. J., et al., 1996, “A dose-ranging study of a prototype synthetic HIV-1MN branched peptide vaccine”, J. Infect. Dis. 173(2):330-339 (abstract provided).
Burton, D. R., and J. P. Moore, 1998, “Why do we not have an HIV vaccine and how can we make one?”, Nat. Med. Vac. Suppl. 4(5):495-498.
Moore, J. P., and D. R. Burton, 1999, “HIV-1 neutralizing antiobodies: How full is the bottle?”, Nat. Med.5(2):141-144.
McMichael, A. J., and T. Hanke, 2003, “HIV vaccines 1983-2003”, Nat. Med. 9(7):874-880.
Desrosiers, R.C., 2004, “Prospects for an AIDS vaccine”, Nat. Med. 10(3):221-223.
Haigwood, N. L., 2004, “Predictive value of primate models for AIDS”, AIDS Rev. 6:187-198.
Gallo, R. C., 2005, “The end or the begining of the drive to an HIV-positive vaccine: a view from over 20 years”, Lancet 366:1894-1898.
Buratti et al. “A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE” Journal of Virology, vol. 71, No. 3, 1997 pp. 2457-2462.
Caruso Arnaldo
Franzone Jose Sebastian
Medestea Internazionale S.r.l.
Merchant & Gould P.C.
Parkin Jeffrey S.
LandOfFree
Human immunodeficiency virus type 1 (HIV-1) matrix (MA or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human immunodeficiency virus type 1 (HIV-1) matrix (MA or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human immunodeficiency virus type 1 (HIV-1) matrix (MA or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4079219